PedsCrit

PRoMPT BOLUS Trial with Drs. Balamuth, Weiss, and Kupperman

Jul 6, 2026
Fran Balamuth, pediatric sepsis researcher at CHOP; Scott Weiss, critical care chief and sepsis expert at Nemours; and Nathan Kuppermann, emergency physician and clinical trialist, discuss the landmark PRoMPT BOLUS trial. They explore its global, pragmatic design, enrollment of 9,041 children, MAKE30 kidney outcomes, balanced fluids versus saline, guideline implications, Phoenix criteria, and forthcoming biomarker analyses.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
ANECDOTE

How Global Networks Made PRoMPT BOLUS Possible

  • Nathan Kuppermann built PRoMPT BOLUS through international emergency research networks rather than relying on PECARN alone.
  • Four grants across the United States, Canada, Australia, and New Zealand provided roughly $10 million and capacity for 10,000 patients.
INSIGHT

Pragmatic Criteria Captured Real ED Sepsis Decisions

  • The trial deliberately enrolled clinicians’ real-world suspected septic shock population instead of requiring confirmed sepsis.
  • Physicians included children they planned to treat with at least two boluses for hypotension or poor perfusion.
INSIGHT

Why MAKE30 Was More Useful Than Mortality Alone

  • MAKE30 combined death, renal replacement therapy, and persistent kidney dysfunction through discharge or 30 days.
  • Persistent dysfunction matters because pediatric sepsis survivors face higher later chronic kidney disease risk, healthcare use, and costs.
Get the Snipd Podcast app to discover more snips from this episode
Get the app